Drug
Semapimod
Semapimod is a pharmaceutical drug with 4 clinical trials. Historical success rate of 75.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_2
4
100%
Phase Distribution
0
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Terminated(1)
Detailed Status
Completed3
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 2
Trials by Phase
Phase 24 (100.0%)
Trials by Status
completed375%
terminated125%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease
NCT00740103
completedphase_2
Extension Study of Semapimod 60 mg IV x 3 Days
NCT00741910
completedphase_2
Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo
NCT00739986
terminatedphase_2
CNI-1493 for Treatment of Moderate to Severe Crohn's Disease
NCT00038766
Clinical Trials (4)
Showing 4 of 4 trials
NCT00740103Phase 2
Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease
NCT00741910Phase 2
Extension Study of Semapimod 60 mg IV x 3 Days
NCT00739986Phase 2
Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo
NCT00038766Phase 2
CNI-1493 for Treatment of Moderate to Severe Crohn's Disease
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4